Target intelligence / Profile preview

DNA polymerase theta helicase domain (POLQ-hel)

Target
POLQ-hel
Molecular classification
Enzyme (helicase and polymerase), DNA repair protein
01

Overview

The DNA polymerase theta helicase domain (sometimes referred to as Polθ-hel) is the N-terminal domain of DNA polymerase theta (POLQ), a unique mammalian enzyme essential for DNA repair via microhomology-mediated end joining (MMEJ). The helicase domain has relatively weak 3′–5′-direction ATP-dependent DNA unwinding activity and strong ATP-independent single-stranded DNA annealing, and it is structurally distinct from other SF2 family helicases. It efficiently dissociates single-stranded DNA-binding proteins (e.g., the RPA complex), thereby facilitating the bridging and joining of broken DNA ends required for MMEJ. The helicase domain can form dimers or tetramers, likely aiding the alignment of broken DNA for repair. Due to its role in cancer cell survival (particularly in tumors with defective homologous recombination, such as BRCA-mutant cancers), the Polθ helicase has emerged as a promising drug target. The small-molecule inhibitor AB25583 specifically binds the helicase channel, inhibits its ATPase activity, and selectively kills BRCA-deficient cells, underscoring the clinical potential of targeting this domain for precision oncology.

Other names
Polθ helicasePOLQ-helDNA polymerase theta helicaseDNA polymerase theta HLD (helicase-like domain)POLQ helicase domain
02

Mechanism of action

Inhibition of ATPase and DNA unwinding/annealing activities, Allosteric modulation of the helicase conformational state

03

Biological functions

DNA double-strand break repair (especially microhomology-mediated end joining)Strand annealingRemoval of single-stranded DNA-binding proteins (e.g., dissociation of RPA complex)Low-fidelity DNA synthesis
04

Disease associations

Cancer (especially BRCA-mutant and homologous recombination-deficient cancers)Chromosomal instability
05

Safety considerations

Potential impact on normal DNA repair may increase genomic instability in healthy cellsRisk of unintended effects due to inhibition of other DNA repair mechanisms (not fully understood)
06

Interacting drugs

AB25583 (experimental small-molecule inhibitor targeting Polθ helicase)
07

Biomarkers

BRCA1/2 mutation status (predicts synthetic lethality for Polθ inhibition)POLQ expression levels (upregulated in certain tumors)

Beyond the preview

Go deeper on DNA polymerase theta helicase domain (POLQ-hel).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA polymerase theta helicase domain (POLQ-hel).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call